Background
==========

To investigate the effects of high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) both clinically and on the synovial infiltrate for selected patients with severe, refractory RA.

Methods
=======

12 patients with rheumatoid arthritis, were treated. Mobilization of autologous blood stem cells was accomplished with cyclophosphamide (4 g/m^2^) and G-CSF. The conditioning regimen consisted of intravenous administration of high dose cyclophosphamide (totalling 200 mg/kg), with subsequent reinfusion of the positively selected graft. Biopsies of synovial tissue from a knee were obtained before and three months after HDC and ASCT. Immunological monitoring and immunohistochemistry on the synovial infiltrate was performed.

Results
=======

The procedure appeared feasible in all patients. The aplastic period lasted less than 4 weeks in all patients. Efficacy data, with follow-up ranging from 6--24 months showed that the mean disease activity score (DAS) decreased from 5.4 (n = 12) to 3.2 at 6 months (n = 12, *P* = 0.003), 3.1 at 12 months (n = 11, *P* = 0.005) and 2.9 at 24 months (n = 5, *P* = 0.043). Mean DMARD-free period was 12.9 months (95% CI: 7.23--18.48). Patients could be classified in clinical responders (Good response (Eular); ACR \>50%, n = 6) and non-responders (Moderate or no response; ACR ≤20%, n = 6) at three months post-transplantation. Immunophenotyping of PBMCs showed prolonged (\>24 months) depletion of CD45RA+ T cells after transplantation, whereas levels of CD8+, CD3-CD16CD56+ and CD19+ cells quickly recovered. CD4+CD45RO+ cells were not complety depleted after transplantation. High IgG1 in peripheral blood (responders: 9.69 g/l; non-responders 6.24 g/l *P* = 0.046) and high baseline synovial CD27 (mean infitration score; 3 vs. 0.33; *P* = 0.036) and CD45RO (mean infiltration score; 3.4 vs. 0.67; *P* = 0.036) predicted clinical response. Furthermore there were trends towards a decrease in T-cell markers in the synovium before and after transplantation were compared (CD3-CD4-CD25-CD45RA-RO and CD27), but no statistical significant differences were found. IL-1 showed significant higher scores in non-responders than responders after transplantation: 3.5 vs. 0.6 (*P* = 0.024).

Conclusions
===========

The results of the present interim-analysis underscore the feasibility and potential efficacy of HDC followed by ASCT for the treatment of intractable RA. Clinical effect of HDC and ASCT correlated with T-cell debulking in synovial tissue.
